PURPOSE: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. METHODS: The Florida Cancer Data System was queried from 1981 to 2004. RESULTS: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6%, 67.7%) and COG/LVC (75.8%, 72.6%) than non-COG/LVC (59.5%, 54.4%, P < 0.05). Of 790 WT patients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3%, 89.9%) and COG/LVC (96.7%, 94.7%) than non-COG/LVC (82.4%, 81.7%, P < 0.05). Multivariate analysis demonstrated WT patients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). CONCLUSION: Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Copyright 2010 Wiley-Liss, Inc.
PURPOSE: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival. METHODS: The Florida Cancer Data System was queried from 1981 to 2004. RESULTS: Of 869 NBL patients, 463 were treated at COG/HVC, 246 at COG/LVC, and 160 at non-COG/LVC. COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005). COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (70.6%, 67.7%) and COG/LVC (75.8%, 72.6%) than non-COG/LVC (59.5%, 54.4%, P < 0.05). Of 790 WTpatients, 395 were treated at COG/HVC, 210 at COG/LVC, and 185 at non-COG/LVC. COG hospitals treated younger patients and lower staged tumors (P < 0.05). COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001). Five- and 10-year survival rates were higher at COG/HVC (91.3%, 89.9%) and COG/LVC (96.7%, 94.7%) than non-COG/LVC (82.4%, 81.7%, P < 0.05). Multivariate analysis demonstrated WTpatients treated at non-COG hospitals, but not NBL patients, had worse survival (HR 3.107, P = 0.01). CONCLUSION:Children treated at COG hospitals had higher overall use of chemotherapy. This translated into a significantly improved survival benefit for WT. Copyright 2010 Wiley-Liss, Inc.
Authors: Christopher M Dodgion; Bridget A Neville; Stuart R Lipsitz; Deborah Schrag; Elizabeth Breen; Michael J Zinner; Caprice C Greenberg Journal: J Surg Res Date: 2014-03-22 Impact factor: 2.192
Authors: Jennifer J Wilkes; Sean Hennessy; Rui Xiao; Susan Rheingold; Alix E Seif; Yuan-Shung Huang; Neika Vendetti; Yimei Li; Rochelle Bagatell; Richard Aplenc; Brian T Fisher Journal: Clin Lymphoma Myeloma Leuk Date: 2016-05-04
Authors: Mary T Austin; Hoang Nguyen; Jan M Eberth; Yuchia Chang; Andras Heczey; Dennis P Hughes; Kevin P Lally; Linda S Elting Journal: J Pediatr Surg Date: 2014-10-26 Impact factor: 2.545
Authors: Prakriti Roy; Sophie E van Peer; Martin M de Witte; Godelieve A M Tytgat; Henrike E Karim-Kos; Martine van Grotel; Cees P van de Ven; Annelies M C Mavinkurve-Groothuis; Johannes H M Merks; Roland P Kuiper; Janna A Hol; Geert O R Janssens; Ronald R de Krijger; Marjolijn C J Jongmans; Jarno Drost; Alida F W van der Steeg; Annemieke S Littooij; Marc H W A Wijnen; Harm van Tinteren; Marry M van den Heuvel-Eibrink Journal: PLoS One Date: 2022-01-13 Impact factor: 3.240